Analysts at Leerink maintain an Outperform rating on shares ofClovis Oncology Inc (NASDAQ: CLVS) with a price target boosted from $85 to $114 after the company hosted a conference call on Monday, which addressed some of the biggest controversies it faces.
Latest Ratings for CLVS
|Jun 2017||Janney Capital||Upgrades||Neutral||Buy|
|Jun 2017||Chardan Capital||Upgrades||Sell||Neutral|
|Jun 2017||Leerink Swann||Initiates Coverage On||Outperform|